Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting

NORCROSS, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based...
October 15, 2018 10:22 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference

NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
October 15, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference

NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
September 20, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial

Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33%...
August 28, 2018 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

NORCROSS, Ga., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
August 14, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
June 27, 2018 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
June 12, 2018 08:32 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Announces New CEO

NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H....
June 04, 2018 09:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board

NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors...
May 14, 2018 09:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting

NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with...